<DOC>
	<DOCNO>NCT00959517</DOCNO>
	<brief_summary>This study evaluation benefit add artesunate exist first second line antimalarial therapy Pakistan . A placebo control trial carry assess two potential benefit Artesunate Combination Therapy ( ACT ) : efficacy potential transmission reduction .</brief_summary>
	<brief_title>Trial Artesunate Combination Therapy Pakistan</brief_title>
	<detailed_description>A randomised , double-blind placebo control study efficacy chloroquine sulphadoxine-pyrimethamine alone combination primaquine artesunate treatment uncomplicated falciparum malaria . Arms : 1 . CQ 2 . CQ+primaquine 3 . CQ+ artesunate 4 . SP 5 . SP+primaquine 6 . SP+artesunate Patients allocate treatment group use pseudo-randomised table split age sex . Primary outcome : - Clinical parasitological cure/treatment failure day 28 . Secondary outcome : - time resolution fever - time clearance trophozoites - time clearance gametocyte - gametocyte carriage day 7 treatment All clinical assessment slide reading carry staff blind treatment arm . Slides double read .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Falciparum</mesh_term>
	<mesh_term>Fanasil , pyrimethamine drug combination</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Chloroquine diphosphate</mesh_term>
	<mesh_term>Sulfadoxine</mesh_term>
	<mesh_term>Pyrimethamine</mesh_term>
	<mesh_term>Primaquine</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Chloroquine</mesh_term>
	<criteria>presentation basic health unit suspect clinical malaria monoinfection infection P. falciparum confirm microscopy 2 year age ( upper age restriction ) weight 5 kg ( upper weight restriction ) child bear age nonpregnant willing remain duration study great 1 asexual parasite per 10 field understands willing sign consent form resident study site willing collaborate full period followup sign severe malaria serious disease ( e.g. , cardiac , renal hepatic ) woman child bear age , pregnancy allergy study drug related compound report use malaria drug last 21 day specie malaria see sign severe malaria</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Placebo control</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Artemisinin-based combination therapy</keyword>
	<keyword>Primaquine</keyword>
	<keyword>Gametocytes</keyword>
</DOC>